top of page
Unmet Need
Current treatments fail up to 50% of nAMD patients, resulting in significant vision loss or blindness. Additionally, up to 67% of patients still experience persistent retinal fluid after two years of treatment.
​
Prevalence and Incidence: Approximately 1.5-1.7 million Americans are affected,
with around 300,000 new cases annually.

Innovative Solution
Orsight Pharma is developing a First-in-class drug aimed at preserving vision and preventing blindness through a breakthrough mechanism, offering new hope for those unresponsive to existing treatments.
​
- Small Molecule Advantage
- Prevents Blindness Through a Unique Mechanism
- Slow Release Formulation
- Complementary to Current Treatments
​
bottom of page